New complaints against Bayer Healthcare and Johnson & Johnson continue to be filed across the U.S. regarding the drug-makers blood-thinner Xarelto. As early as next week, oral arguments over whether to consolidate existing federal Xarelto lawsuits will be heard by the U.S. Judicial Panel on Multidistrict Litigation. The complaints pending consolidation all involve similar allegations that the Companies failed to adequately warn against the adverse side effects the anticoagulant can cause— including severe, unstoppable, and sometimes fatal, bleeding — and that the injuries sustained could have been prevented if the drug giants provided stronger warnings. Xarelto lawsuits have doubled over the past month, and are expected to mushroom dramatically once the panel decides whether to allow a Xarelto multi-district litigation (MDL) case to proceed. An MDL can expedite proceedings in a more efficient manner, and can also help gauge how juries will respond to evidence and testimony that is likely to be repeated throughout future litigation.